INTRODUCTION

45
Hepatitis B virus (HBV) infection remains a major global health problem with 46 an estimated 240 million chronically infected people worldwide (Grimm et (Zoulim and Durantel, 2015) . Each agent has individual advantages and drawbacks. 78 Interferon is costly, poorly tolerated, and only responsive in a small fraction of CHB hepatocytes cannot be achieved by any of the aforementioned drugs and compounds. 
Cell Viability Assay
160
The effect of testing compounds on cell viability was measured by using the 161 CellTiter-Glo reagent (Promega) according to the manufacturer's instructions. mRNA, a pair of primers flanking the X ORF region was utilized to amplify HBV 301 total RNA (Fig. 3A) . As shown in Fig. 3B , the treatment of punicalagin significantly remained unchanged under 3TC or punicalagin treatment (Fig. 3B) .
311
Next, we tested punicalagin in HepG2.2.15 cells, in which all the viral RNAs 312 are constitutively and predominately transcribed from the integrated HBV genome.
313
As shown in Fig. 3C had an obvious effect until the treatment was extended to 6 days (Fig.4 B) . Taken   350 together, these results demonstrated that punicalagin has a direct down-regulative 351 effect on the accumulation of cccDNA. molecules (Fig. 6 ). In addition, the degradation of DP-rcDNA during active virus 445 replication, if any, was negligible (Fig. 5A) . Thus, we speculated that tannins, 446 especially geraniin, possess a major antiviral activity against cccDNA formation. 
